INFORMATION DISCLOSURE **STATEMENT** PTO-1449

ATTY. DOCKET NO. 0047.10

SERIAL NO. 10/601,127

APPLICANT Schuler, et al.

FILING DATE June 19, 2003

GROUP ART UNIT: 3761

JUN 2 6 2006

Page 1 of 7

ILS. PATENT DOCUMENTS

	7	U.S. PATENT DOCUMENTS						
INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
/DE/	2,587,215	02/1952	Priestly					
	3,788,310	01/1974	Fleischmann					
	3,837,341	09/1974	Bell					
	4,086,918	05/1978	Russo					
	4,106,503	08/1978	Rosenthal, et al.					
	4,114,608	09/1978	Russo					
	4,170,228	10/1979	Elson, et al.					
	4,259,951	04/1981	Chernack, et al.					
	4,274,404	06/1981	Molzan, et al.					
	4,284,083	08/1981	Lester					
	4,338,931	07/1982	Cavazza					
	4,391,283	07/1983	Sharpless, et al.					
	4,442,856	04/1984	Betz					
	4,444,202	04/1984	Rubin, et al.					
	4,484,577	11/1984	Sackner, et al.					
	4,495,944	01/1985	Brisson, et al.					
	4,533,137	08/1985	Sonne					
	4,558,710	12/1985	Eichler					
	4,592,348	06/1986	Waters, et al.					
	4,627,432	12/1986	Newell, et al.					
	4,677,975	07/1987	Edgar, et al.					
	4,778,054	10/1988	Newell, et al.					
	4,811,731	03/1989	Newell, et al.					
	4,907,583	03/1990	Wetterlin, et al.					
	4,926,852	05/1990	Zoltan, et al.					
	4,955,371	09/1990	Zamba, et al.					
	4,991,745	02/1991	Brown	222	212			
$\bot V$	5,027,806	07/1991	Zoltan, et al.			- 5		

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO. SERIAL NO. 10/601,127 APPLICANT Schuler, et al.			
	Page 2 of 7		FILING DATE June 19, 20	003 G	ROUP ART U	NIT: 3761
		U.	S. PATENT DOCUMENTS			
/DE/	5,033,655	07/1991	Brown	222 .	212	
	5,040,527	08/1991	Larson, et al.			
	5,042,467	08/1991	Foley	128	200.23	
	5,042,472	08/1991	Bunin			
	5,069,204	12/1991	Smith, et al.			
	5,167,506	12/1992	Kilis, et al.			
	5,184,641	02/1993	Kuhn			
	5,201,308	04/1993	Newhouse			
	5,213,236	05/1993	Brown, et al.	222	185	
	5,284,133	02/1994	Burns, et al.			-
	5,301,666	04/1994	Lerk, et al.			
	5,320,094	06/1994	Laube, et al.			
	5,333,106	07/1994	Lanpher, et al.			
	5,339,995	08/1994	Brown, et al.	222	185	
	5,364,838	11/1994	Rubsamen, et al.			
	5,377,877	01/1995	Brown, et al.	222	105	
	5,385,140	01/1995	Smith	<u> </u>		
	5,408,994	04/1995	Wass, et al.	1		
	5,409,144	04/1995	Brown, et al.	222	185	
	5,419,315	05/1995	Rubsamen			
	5,435,301	07/1995	Herold			
	5,437,271	08/1995	Hodson, et al.	1		
	5,439,143	08/1995	Brown, et al.	222	185	
	5,447,150	09/1995	Bacon			
	5,447,151	09/1995	Bruna, et al.	 		
	5,458,135	10/1995	Patton, et al.	128	200.14	
	5,483,954	01/1996	Mecikalski			
	5,497,944	03/1996	Weston, et al.	128	200.14	
\/	5,509,404	04/1996	Lloyd, et al.			

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO. SERIAL NO. 10/601,127 APPLICANT Schuler, et al.			
	Page 3 of 7		FILING DATE June 19, 200	3 GR	OUP ART UN	NIT: 3761
		U.S	S. PATENT DOCUMENTS	<u> </u>		
/DE/	5,513,630	05/1996	Century			
	5,522,380	06/1996	Dwork	128	200.23	
	5,529,059	06/1996	Armstrong, et al.			
	5,533,505	07/1996	Kallstrand			
	5,542,412	08/1996	Century			
	5,558,085	09/1996	Rubsamen, et al.			
	5,568,807	10/1996	Mecikalski	128	203.21	
	5,586,550	12/1996	Ivri, et al.			
	5,617,845	04/1997	Poss, et al.			
	5,622,166	04/1997	Eisele, et al.	128	203.12	
	5,653,223	08/1997	Pruitt	128	200.21	
	5,654,007	08/1997	Johnson, et al.	424	489	
	5,655,520	08/1997	Howe, et al.	128	203.12	
	5,672,581	09/1997	Rubsamen			
	5,692,492	12/1997	Bruna, et al.			
	5,692,496	12/1997	Casper, et al.			
	5,692,498	12/1997	Lurie, et al.	128	205.24	
	5,699,789	12/1997	Hendricks			
	5,724,959	03/1998	McAughey, et al.			
	5,727,546	03/1998	Clarke, et al.			
	5,740,794	04/1998	Smith, et al.	128	203.15	
	5,752,505	05/1998	Ohki, et al.	128	203.15	
	5,775,320	07/1998	Patton, et al.	128	200.14	
	5,785,049	07/1998	Smith, et al.	128	203.15	
	5,813,401	09/1998	Radcliff, et al.			
	5,823,183	10/1998	Casper, et al.			
	5,826,571	10/1998	Casper, et al.			
	5,826,633	10/1998	Parks, et al.	141	489	
LV	5,855,202	01/1999	Andrade			

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO. SERIAL NO. 0047.10 10/601,127 APPLICANT Schuler, et al.			
	<u>Page 4 of 7</u>		FILING DATE June 19, 20	03 G	ROUP ART UN	VIT: 3761
			S. PATENT DOCUMENTS			<u> </u>
/DE/	5,873,358	02/1999	Gonda, et al.			
	5,875,776	03/1999	Vaghefi, et al.			
	5,881,719	03/1999	Gottenauer, et al.	128	203.15	
	5,884,620	03/1999	Gonda, et al.			
	5,896,853	04/1999	Howlett			
	5,901,703	05/1999	Ohki, et al.	128	200.14	
	5,921,237	07/1999	Eisele			
	5,922,354	07/1999	Johnson, et al.	424	489	
	5,941,240	08/1999	Gonda, et al.			
	5,975,076	11/1999	Yianneskis			
	5,983,893	11/1999	Wetterlin			
	5,988,163	11/1999	Casper			
	5,993,421	11/1999	Kriesel			
	6,006,747	12/1999	Eisele			
	6,012,454	01/2000	Hodson, et al.			
	6,029,661	02/2000	Whaley, et al.			
	6,029,663	02/2000	Eisele, et al.	128	203.21	
	6,055,979	05/2000	Fuchs			
	6,055,980	05/2000	Mecikalski	1		
	6,062,219	05/2000	Lurie, et al.			
	6,065,472	05/2000	Anderson, et al.	128	203.21	
	6,070,573	06/2000	Howe, et al	 		†
	6,076,523	06/2000	Jones, et a.	1		
	6,085,753	07/2000	Gonda, et al.	 		
	6,089,228	07/2000	Smith, et al.	128	203.15	
	6,095,134	08/2000	Sievers, et al.		 	
	6,102,036	08/2000	Slutsky, et al.			
	6,105,574	08/2000	Jahnsson			-
	6,109,261	08/2000	Clarke, et al.	-	1	
$ \Lambda$	6,116,237	09/2000	Schultz, et al.	†		

								71 101
INFORM	ATION DISCLO	OSURE	ATTY. DOCKET NO.		SEF	RIAL NO.		
	STATEMENT	DOULL	0047.10		10/6	501,127		
	PTO-1449		APPLICANT Schuler, et al.	l .				
	<u>Page 5 of 7</u>		FILING DATE June 19, 200	03	GR	OUP ART UN	IT: 376	<u> </u>
		U.S	S. PATENT DOCUMENTS	1				
/DE/	6,116,238	09/2000	Jacksone, et al.	1:	28	203.15		
	6,116,239	09/2000	Volgyesi					
	6,138,673	10/2000	Shepard	12	28	203.15		
	6,142,146	11/2000	Abrams, et al.					
	6,161,524	11/1992	Evans	1				
V	6,176,237	01/2001	Wunderlich, et al.	12	28	203.12		
							-	
				†				
		FOR	EIGN PATENT DOCUMENTS	3		4		
EXAMINER'S INITIALS	EXAMINER'S PATENT NO. DATE		COUNTRY	CL	ASS	SUBCLASS	TRANS	SLATION
							YES	NO
/DE/	WO 91/14422	10/1991	PCT/US					
	WO 96/09085	03/1996	PCT/US					
	WO 96/32149	10/1996	PCT/US					
	WO 98/32479	07/1998	PCT					
	WO 99/46055	09/1999	PCT					
	WO 99/16419	09/1997	US					
	WO 95/24183	02/1995	US					
	WO 99/47196	03/1999	US					
	WO 95/34337	12/1995	PCT					
	WO 97/40819	11/1997	PCT					
	WO 99/27987	06/1999	PCT	1				
	WO 96/30068	10/1996	PCT					
	WO 00/21594	04/2000	PCT					
	WO 00/01435	01/2000	PCT	\top		ر		
	EP 0808635A2	11/1997	Europe	\top				
V	EP 0714314B1	10/1998	Europe	1			П	

$\overline{}$				T					
INF	ORMA	TION DISCLO	OSURE	ATTY. DOCKET NO.	SE	RIAL NO.			
	S	TATEMENT	/	0047.10	10/	/601,127			
		PTO-1449	!	APPLICANT Schuler, et al.					
		Page 6 of 7		FILING DATE June 19, 200)3 GR	ROUP ART UN	IT: 376	1	
			FOR	EIGN PATENT DOCUMENTS					
/DI	E/	EP 0805696B1	03/2000	Europe					
		HU 212398	06/1996	Boehringer					
		HU 219215	03/2001	Merck					
		HU 214757	05/1998	Asta					
V	7	1,598,053	09/1981	United Kingdom					
		OTHER DO	CUMENTS ((Including Author, Title, Date, Pe	ertinent P	ages, Etc.)			
/D	E/	1	Flow Targeting	g System for DPI Clinical Trials, "			esearch		
		Prime, D., et al. simulator," Glav	"The Flixotide xo Research as	le Diskus a new multi powder inhal and Development, pp 138.	ler-in-vitro	evaluation using	g an inhal	ation	
		Prime, D., et al. "The Flixotide Diskus a new multi powder inhaler-consistency of dose and fine particle mass, protection from moisture," Glaxo Research and Development, pp 137.							
		Robertson, D.L.: performance," S	N., et al., "The School of Phar	e influence of (pseudo) polymorphi macy and Pharmacology, pp. 139	ic for,s of	lactose on dry po	wer inhal	ler	
		Barrowcliffe, et Pharmaceuticals		/itro Evaluation of Novel Multi-Do.	ose Dry Po	wer Inhaler," CC	.L		
		Malton, et al., "/ European Journ	A Comparison al of Clinical	n of <i>in vitro</i> drug delivery from two Research, 1995:7; pp. 177-193.) multidose	powder inhalation	on device	÷s,"	
		Agenda for Asthu Critical Care Me	ma Therapy I edicine, 153(4	– Thematic Poster Session May 12), April 1996.	2, <i>1996</i> , Ar	nerican Journal c	of Respira	atory	
İ		Malton, et al., "A inhalers," J. Pha	A Comparison urm. Med., (19	n of <i>in vitro</i> drug delivery from slab 1996) 6, pp. 35-48.	outamol Di	skus and terbutal	line Turbo	ohaler	
		Chrystyn, Henry Drug Invest., 18(7, "The Diskus (4):pp. 287-29	s Inhaler- A Review of its Pharmaco 96 (1999).	eutical and	l Clinical Perform	nance," C	Clin.	
	<u> </u>	Newhouse, et al. Pressurized Met	, "Clickhaler (ered-Dose Inh	(a Novel Dry Powder Inhaler) Prov naler, Even at Low Flow Rates," <i>CF</i>	vides simil HEST 115(ar Bronchodolata (4):pp. 952-956:	ition to April 199	19.	
* ·		Clark, "Effect of Delivery IV, 199	powder inhal- 94.	ler resistance upon inspiratory profi	iles in heal	Ith & disease," Re	espirator	Drug	
		Clark, "The relat volunteers - imp	ionship betwe olications for i	een powder inhaler resistance and p in vitro testing," <i>Journal of Aerosol</i>	peak inspri l Science,	atry conditions ir 1993.	1 healthy		
		"Characteristics	of an active m	nultiple dose dry powder inhaler," I	Dura RDD	, 1994.			
	/	Dolovich, "Phys	ical principles	s underlying aerosol therapy," Journ	rnal of Aer	osol Medicine, 19	989.		

INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0047.10	SERIAL NO. 10/601,127			
	PTO-1449	APPLICANT Schuler, et al.				
·	Page 7 of 7	FILING DATE June 19, 2003	GROUP ART UNIT: 3761			
	OTHER DOCUMENTS	Including Author, Title, Date, Pertin	ent Pages, Etc.)			
	Elliott, et al., "Parental absort 23, pp. 293-297 (1987).	otion of insulin from the lung in diabetic	children," Aust. Paediatric Journal,			
/DE/	Lawford, et al., "Pressurized Aerosol Inhaler Technique: How Important are Inhalation from Residual Volume, Inspiratory Flow Rate and the Time Interval Between Puffs?", Br. J. Dist. Chest, 77, pp. 276-281 (1983).					
/DE/	Ross, et al., "Effect of Inhalat Metered Dose Inhaler (MDI)	ion Flow Rate on the Dosing Characteri Products," Journal of Aerosol Medicine	stics of Dry Powder Inhaler (DPI) and , Vol. 9, No. 2., pp. 215-226 (1996).			
	Hill, "Characteristics of an Active, Multiple Dose Dry Powder Inhaler," Respiratory Drug Delivery IV, pp. 109-116 (1994).					
/DE/	Conway, et al., "Comparison of peak Pressure Drops Through Powder Inhalers During Inspiration at Maximum Flow Rate" Abstract from American Journal of Respiratory and Critical Care Medicine, Vol. 153, No. 4, A59, (April 1996).					
EXAMINER	/Darwin Erezo/	DATE CONSIDERED 04/19	/2007			

OIPE	Forn
OCT 2 7 2008	95) (CE
THE TRADEME	<i>\$</i> /

Form PTO/SB/08A (I	Modified
--------------------	-----------------

Information Disclosure Statement By Applicant

(Use Several Sheets	if Necessary)
---------------------	---------------

Atty Docket No.:	Application No.:
0047.10	10/601,127
pplicant:	
Carlos	SCHULER et al.
iling Date:	Group:
06/19/2003	3731

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	Class	Date
/DE/		5,161,524	11/10/92	Evans, Rix E.			
	<u></u>		<u> </u>				
			! 				
				<u> </u>			

			<u> </u>		-		
					 		
					1		
			_				
		<u></u>		<u> </u>			

/Darwin Erezo/

04/19/2007

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.